Literature DB >> 16807060

The role of G-CSF in adaptive immunity.

Anke Franzke1.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) is a pleiotropic cytokine playing a major role as regulator of hematopoiesis and innate immune responses. There is growing evidence that G-CSF also exerts profound immunoregulatory effects in adaptive immunity. G-CSF mediates anti-inflammatory reactions accompanied by TH2 cell differentiation and promotes tolerogeneic cell populations at both poles of APC/T cell interaction. These recent findings have highlighted the novel impact of G-CSF in transplantation tolerance and autoimmunity. G-CSF represents a powerful and promising cytokine to promote T cell tolerance in pathological conditions associated with a TH1/TH2 imbalance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807060     DOI: 10.1016/j.cytogfr.2006.05.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  18 in total

1.  Neuroprotective effects of G-CSF administration in microglia-mediated reactive T cell activation in vitro.

Authors:  Wei Peng
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

2.  Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.

Authors:  James Krempski; Lavakumar Karyampudi; Marshall D Behrens; Courtney L Erskine; Lynn Hartmann; Haidong Dong; Ellen L Goode; Kimberly R Kalli; Keith L Knutson
Journal:  J Immunol       Date:  2011-05-06       Impact factor: 5.422

3.  Effect of TGF-β1 Stimulation on the Secretome of Human Adipose-Derived Mesenchymal Stromal Cells.

Authors:  Tania M Rodríguez; Alejandro Saldías; Marcelo Irigo; Jorge Velasco Zamora; Marcelo J Perone; Ricardo A Dewey
Journal:  Stem Cells Transl Med       Date:  2015-05-29       Impact factor: 6.940

4.  Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naïve T cells.

Authors:  Maura Rossetti; Silvia Gregori; Maria Grazia Roncarolo
Journal:  Eur J Immunol       Date:  2010-10-19       Impact factor: 5.532

Review 5.  New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.

Authors:  X Chang; X Zang; C Q Xia
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

6.  G-CSF drives a posttraumatic immune program that protects the host from infection.

Authors:  Jason C Gardner; John G Noel; Nikolaos M Nikolaidis; Rebekah Karns; Bruce J Aronow; Cora K Ogle; Francis X McCormack
Journal:  J Immunol       Date:  2014-01-27       Impact factor: 5.422

7.  Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.

Authors:  Y A Aldhamen; S S Seregin; Y A Kousa; D P W Rastall; D M Appledorn; S Godbehere; B C Schutte; A Amalfitano
Journal:  Cancer Gene Ther       Date:  2013-08-16       Impact factor: 5.987

8.  Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application.

Authors:  Sya N Ukena; Sarvari Velaga; Lilia Goudeva; Philipp Ivanyi; Sven Olek; Christine S Falk; Arnold Ganser; Anke Franzke
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Morphine reduces local cytokine expression and neutrophil infiltration after incision.

Authors:  J David Clark; Xiaoyou Shi; Xiangqi Li; Yanli Qiao; DeYong Liang; Martin S Angst; David C Yeomans
Journal:  Mol Pain       Date:  2007-10-02       Impact factor: 3.395

10.  Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor.

Authors:  Carola E Bunse; Sylvia Borchers; Pavankumar R Varanasi; Sabine Tischer; Constança Figueiredo; Stephan Immenschuh; Ulrich Kalinke; Ulrike Köhl; Lilia Goudeva; Britta Maecker-Kolhoff; Arnold Ganser; Rainer Blasczyk; Eva M Weissinger; Britta Eiz-Vesper
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.